Search for Stocks /

Gennex Laboratories Ltd Q3 FY26: ₹42.96 Cr Sales, ₹6 Cr Profit, 19.95% OPM — Yet Stock Down 17% in 3 Months. Hidden API Comeback or Just Pharma Mirage?


1. At a Glance – The ₹274 Cr Pharma That Refuses to Act Its Size

Here’s a small-cap pharma doing ₹42.96 crore in quarterly sales, ₹6 crore in quarterly profit, operating margins flirting with 20%, and still trading at just ₹11.3 per share. Market cap? ₹274 crore. P/E? 15.6. Price-to-book? 1.27. ROCE? 13%. ROE? 10.2%.

And yet — the stock is down 17.8% in 3 months and 14.8% in 1 year.

Why?

Because in Dalal Street, size matters. And ₹274 crore companies are treated like interns at a Sun Pharma conference.

But wait. Q3 FY26 (December 2025 quarter) shows:

  • Sales: ₹42.96 crore (up 7.37% QoQ)
  • PAT: ₹6 crore (up 18% QoQ)
  • EPS: ₹0.22 for the quarter
  • OPM: 19.95%

Annualised EPS? ₹0.22 × 4 = ₹0.88
CMP ₹11.3 → Forward P/E ≈ 12.8.

That’s below industry median P/E of 28.6.

So is this a sleepy API exporter quietly compounding?
Or another “almost there” pharma story?

Let’s dissect.


2. Introduction – Small Pharma, Big Aspirations, Modest Drama

Incorporated in 1995, Gennex Laboratories Ltd manufactures bulk drugs and intermediates. That’s code for “we sell the molecules that other pharma companies turn into tablets you swallow.”

They are ISO certified, WHO-GMP certified, and run a vertically integrated Active Pharmaceutical Ingredient (API) business out of Hyderabad with 85+ KL installed capacity.

Translation: They’re legit.

Revenue mix FY23:

  • Sale of products: ~93%
  • Other income: ~6%
  • Other operating revenue: ~1%

Geographical split:

  • India: 58%
  • Vietnam: 14%
  • Egypt: 9%
  • Spain: 6%
  • Peru, Cuba, Guatemala, Germany, Iran — tiny but global footprints.

For a ₹274 crore company, exporting to Vietnam, Egypt, Spain and Latin America isn’t bad.

But here’s the real question:

If they are growing profits at 59% CAGR over 5 years and sales at 20% CAGR over 5 years… why is ROE still stuck at ~10%?

Efficiency issue? Capital dilution? Or just scale problems?

Let’s see.


3. Business Model – WTF Do They Even Do?

Gennex makes APIs and intermediates. Specifically:

  • Guaifenesin – Expectorant
  • Methocarbamol – Muscle relaxant
  • Fexofenadine HCl – Antihistamine
  • Fluconazole – Antifungal
  • Sertraline HCl – SSRI
  • Allopurinol – Gout medicine

So basically — if you cough, itch, cramp, feel depressed, or have uric acid issues… there’s a decent chance some molecule inside your medicine came from companies like Gennex.

They operate a WHO-GMP certified

Join 10,000+ investors who read this every week.
Become a member